Nimodipine: Indication, Dosage, Side Effect, Precaution

Generic Medicine Info Full Generic Medicine Info

Dosage/Direction for Use Administration Contraindications Special Precautions Adverse Reactions Pregnancy Category (US FDA) Overdosage Drug Interactions Food Interaction Action Storage CIMS Class ATC Classification

This information is not country-specific. Please refer to the India prescribing information.

Generic Medicine Info

Administration

Cap: Should be taken on an empty stomach (i.e. At least one hour before food or two hours after food).
Tab: May be taken with or without food. Take consistently, either always w/ or always w/o meals.

Contraindications

Use w/in 1 mth of MI or an episode of unstable angina. Concomitant use w/ potent CYP3A4 inhibitors (e.g. clarithromycin, ritonavir, ketoconazole, nefazodone).

Special Precautions

Patients w/ cerebral oedema or severely raised intracranial pressure. Contents of oral capsules should be given only by mouth or through a feeding tube. It must never be administered IV or by any other parenteral route. Hepatic and renal impairment. Pregnancy and lactation. Monitoring Parameters Careful monitoring of BP and pulse rate.

Adverse Reactions

Hypotension, oedema, ECG abnormalities, palpitations, rebound vasospasm, flushing, fluid retention, lower abdominal discomfort or cramps, constipation, mental depression, headache, lightheadedness, dizziness, dyspnoea, muscle pain, thrombocytopenia, anaemia, rash, pruritus, haematoma, diaphoresis.

Pregnancy Category (US FDA)

Drug Interactions

Plasma concentration and efficacy may be significantly reduced when administered w/ strong CYP3A4 inducers (e.g. rifampicin, carbamazepine, phenobarbital, phenytoin). May increase serum levels and toxicity of phenytoin. Increased plasma concentrations w/ cimetidine or sodium valproate.

CIMS Class

Nootropics & Neurotonics/Neurotrophics / Peripheral Vasodilators & Cerebral Activators

ATC Classification

C08CA06 - nimodipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.

Disclaimer: This information is independently developed by CIMS based on nimodipine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 CIMS. All rights reserved. Powered by CIMSAsia.com